Form 4: Halozyme CFO Sells Shares Under 10b5-1 Plan

Halozyme Therapeutics' SVP and Chief Financial Officer, Nicole LaBrosse, sold 2,227 shares of common stock through a pre-arranged 10b5-1 trading plan.

Summary

• Nicole LaBrosse, SVP and Chief Financial Officer of Halozyme Therapeutics, Inc. (HALO), reported the sale of common stock.
• The transactions involved two separate sales on September 22, 2025, totaling 2,227 shares.
• The first sale was for 1,913 shares at a weighted average price of $77.827 per share, with prices ranging from $77.34 to $78.32.
• The second sale was for 314 shares at a weighted average price of $78.667 per share, with prices ranging from $78.37 to $79.18.
• These sales were executed by a broker pursuant to a Rule 10b5-1 trading plan adopted by Ms. LaBrosse on June 11, 2025.
• Following these transactions, Ms. LaBrosse beneficially owns 22,079 shares of Halozyme Therapeutics common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the reported sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled personal financial management event rather than a reaction to new material information about the company's performance or outlook.

Future Outlook

NA

Management Comments

• The sales reported were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

Industry Context

This filing reports a routine insider transaction under a pre-arranged trading plan, which is a common practice for executives to manage personal finances while complying with insider trading regulations. It does not provide insights into broader industry trends or competitive landscape.

Key Dates

Recommendation

The sale of shares by a key executive was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled transaction rather than a reaction to new material information. This type of transaction is generally considered neutral and does not typically warrant a change in investment thesis or recommendation based solely on this filing.

Keywords

Halozyme Therapeutics, HALO, Nicole LaBrosse, Form 4, Insider Trading, Stock Sale, 10b5-1 Plan, CFO